Merck announced that the FDA has approved Isentress (raltegravir) for oral suspension, its new pediatric formulation for the treatment of HIV-1 infection.

RELATED: Infectious Diseases Resource Center

Isentress is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients >4 weeks of age, weighing ≥3kg–<20kg. 

Isentress inhibits the catalytic activity of HIV-1 integrase, an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the covalent insertion, or integration, of unintegrated linear HIV-1 DNA into the host cell genome preventing the formation of the HIV-1 provirus. 

Isentress is now available as an oral suspension, chewable tablets, and film-coated tablets. Isentress for oral suspension is expected to be available during the 3rd quarter of 2014.

For more information call (800) 850-3430 or visit